ANO1 and asthma: Finally, because asthma treatment guidelines include β-agonists as a standard of care but allow for add-on therapies for poorly controlled disease, we investigated if TMEM16A antagonists can operate with β-agonists, including under situations of tachyphylaxis or use-dependent desensitization.